Strategic Health Policy Int’l, Inc

We draw upon the experience of our founder as a Presidential Appointee with a $70B portfolio of health programs, a global biopharma Vice President, and counsel to  leaders to serve industry, government, clinical, and advocacy leaders.

• Disease/Condition Expertise:  Alzheimer's Disease, Black Maternal Health, Covid-19, Cancer, Celiac Disease, Depression, Geriatric Depression, Diabetes, Food Allergy, Hepatitis, Men's Health, Ostomy,  Pain Management, Pediatrics, Rare Diseases, Stroke, Vaccines, Veteran's Health, and Women's Health.
• Other Expertise:  Product and Pricing Strategy, Biowarfare Countermeasures, Pandemic Preparedness, Federal and State Government Policy, Crisis Management, Engaging Critics, Professional Society and Patient Advocacy Organization Relations, Public Health, and Treatment Guidelines.

• Successfully leveraged government levers to reduce company costs, increase sales, support innovation, and improve reputation: Pediatric Exclusivity Section 505(A) of the FD&C Act, ACIP Universal Influenza vaccine recommendation, State-level college vaccine mandates, Paul Cloverdale National Acute Stroke Program, WHO Drug Donation Guidelines.
• Unique perspectives based on having held senior leadership positions in government and industry. 
• Known for success in navigating engagements with industry critics.
• Created the first-ever evidence-based messages to support the value of vaccines, protect industry IP, and navigate risk-benefit challenges.